EMLA Cream
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Facial Wrinkles at the Nasolabial Folds
Conditions
Facial Wrinkles at the Nasolabial Folds
Trial Timeline
May 1, 2007 → Jul 1, 2008
NCT ID
NCT00444626About EMLA Cream
EMLA Cream is a phase 3 stage product being developed by Sanofi for Facial Wrinkles at the Nasolabial Folds. The current trial status is completed. This product is registered under clinical trial identifier NCT00444626. Target conditions include Facial Wrinkles at the Nasolabial Folds.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00444626 | Phase 3 | Completed |
Competing Products
13 competing products in Facial Wrinkles at the Nasolabial Folds
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| BOTOX | AbbVie | Approved | 85 |
| OnabotulinumtoxinA + KYBELLA | AbbVie | Approved | 85 |
| BOTOX®/VISTABEL® | AbbVie | Approved | 85 |
| Erenumab Prefilled Syringe | Amgen | Approved | 84 |
| Rapamune | Pfizer | Phase 1 | 32 |
| Diflucortolone valerate (BAY866146) | Bayer | Pre-clinical | 20 |
| Botulinum toxin type A | Ipsen | Phase 3 | 74 |
| IPN10200 + IPN10200 Placebo + Dysport | Ipsen | Phase 1/2 | 38 |
| IPN59011 + Azzalure + Placebo | Ipsen | Phase 1 | 30 |
| Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4) | Baxter | Phase 2 | 49 |
| Metyrosine + Placebo | Bausch Health | Phase 2 | 47 |
| FMX103 minocycline foam 1.5% + Vehicle foam | Vyne Therapeutics | Phase 3 | 69 |
| FMX103 minocycline foam 1.5% + Vehicle foam | Vyne Therapeutics | Phase 3 | 69 |